News articles about Regeneron Pharmaceuticals (NASDAQ:REGN) have trended positive on Saturday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.2058193046846 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Regeneron Pharmaceuticals, Inc. (REGN) Given Average Rating of “Hold” by Analysts (americanbankingnews.com)
- Analysts’ Recommendations for Regeneron in September 2017 (finance.yahoo.com)
- Regeneron Is Focused on Increasing Awareness for Eylea in 2017 (finance.yahoo.com)
- Eylea Leads the Retinal Diseases Sector (finance.yahoo.com)
- Evercore ISI Group Initiates Coverage on Regeneron Pharmaceuticals, Inc. (REGN) Giving It An Initial Rating Of … – First News 24 (firstnewspaper24.com)
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.77% on Friday, reaching $433.45. 1,002,422 shares of the company were exchanged. The company’s 50 day moving average is $472.80 and its 200 day moving average is $445.37. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55. The firm has a market capitalization of $45.96 billion, a PE ratio of 43.48 and a beta of 1.65.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.82 earnings per share. Analysts forecast that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current year.
A number of equities analysts have recently weighed in on REGN shares. Leerink Swann reissued a “positive” rating and set a $552.00 price target (down from $580.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Sanford C. Bernstein reissued an “outperform” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, May 25th. Piper Jaffray Companies reissued an “overweight” rating and set a $557.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. Robert W. Baird reissued a “sell” rating and set a $408.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, September 8th. Finally, Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $605.00 price objective on the stock. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average target price of $491.43.
COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals (REGN) Earns Daily Coverage Optimism Score of 0.28” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://ledgergazette.com/2017/09/17/regeneron-pharmaceuticals-regn-receiving-favorable-media-coverage-report-finds.html.
In related news, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Neil Stahl sold 8,306 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the transaction, the executive vice president now directly owns 43,950 shares of the company’s stock, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. Insiders sold 99,543 shares of company stock valued at $47,831,369 in the last quarter. Corporate insiders own 10.40% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.